NuWays initiates Nexstim with Buy rating, price target EUR 12

• NuWays initiated coverage of Nexstim with a BUY rating, setting a 12-month target price of EUR 12.
• Call centers on NBS System 6 as a modular platform spanning diagnostics, therapy, research, supporting software-led cross-selling.
• NuWays flagged the Brainlab distribution partnership as a potential catalyst, citing Brainlab’s 14,500-system footprint across 6,700 hospitals in 127 countries.
• Forecasts include 18% sales CAGR for 2025-33, EBIT margin rising from about 6% in 2025 to 24% by 2033.
• Gross margin cited at 75%-80%, supporting operating leverage as the installed base expands.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexstim Oyj published the original content used to generate this news brief via EQS News (Ref. ID: rc_26702) on September 02, 2026, and is solely responsible for the information contained therein.